Formulation Strategies for Ezetimibe and Its Combinations: Advancing Biopharmaceutical and Therapeutic Potential
Drug Design, Development and Therapy · 2025-09 · Volume 19 · 8555-8580
DOI: 10.2147/dddt.s550340 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2025-09. Verfasst von Sani Ega Priani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral Program of Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia. Hauptthemen laut MEDLINE: Ezetimibe, Anticholesteremic Agents, Dyslipidemias. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Ezetimibe is a cholesterol absorption inhibitor widely used in the treatment of dyslipidemia. However, its clinical efficacy is limited by poor aqueous solubility and low oral bioavailability. Therapeutic guidelines on dyslipidemia recommend ezetimibe as an adjunct or alternative to statins, particularly in patients who are intolerant to high-dose statins or have inadequate LDL-C reduction. This review summarizes recent advances in ezetimibe formulations, including single-active and combination systems, and discusses their effects on solubility, pharmacokinetics, and therapeutic outcomes. The analysis is based on literature published within the last decade (2015-2025) from reputable scientific databases. Advanced strategies such as solid-state modification, particle size reduction, and lipid or surfactant-based delivery systems have significantly enhanced drug dissolution. In vivo studies report relative bioavailability improvements of approximately 120 to 800% compared to pure drug suspensions/marketed products, translating into favorable pharmacodynamic profiles. Beyond single-active systems, innovative co-delivery with statins such as simvastatin, atorvastatin, rosuvastatin, and lovastatin has demonstrated added pharmacological synergy and supports the development of fixed-dose combination products. Collectively, these advances provide strong evidence that optimized ezetimibe formulations in single-active or combination systems have strong potential to improve the biopharmaceutical profile and future therapeutic application in dyslipidemia management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Doctoral Program of Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
- Faculty of Mathematics and Natural Sciences, Bandung Islamic University, Bandung, Indonesia.
- Department of Pharmaceutics and Technology of Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
- Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
ORCID-Profile: Sani Ega Priani, Anis Yohana Chaerunisaa, Iyan Sopyan
Zitieren
APA
Priani, S. E., Chaerunisaa, A. Y., Wilar, G., & Sopyan, I. (2025). Formulation Strategies for Ezetimibe and Its Combinations: Advancing Biopharmaceutical and Therapeutic Potential. Drug Design, Development and Therapy, Volume 19, 8555-8580. https://doi.org/10.2147/dddt.s550340
Vancouver
Priani SE, Chaerunisaa AY, Wilar G, Sopyan I. Formulation Strategies for Ezetimibe and Its Combinations: Advancing Biopharmaceutical and Therapeutic Potential. Drug Design, Development and Therapy. 2025;Volume 19:8555-8580. doi:10.2147/dddt.s550340
BibTeX
@article{Priani2025,
author = {Priani, Sani Ega and Chaerunisaa, Anis Yohana and Wilar, Gofarana and Sopyan, Iyan},
title = {Formulation Strategies for Ezetimibe and Its Combinations: Advancing Biopharmaceutical and Therapeutic Potential},
journal = {Drug Design, Development and Therapy},
year = {2025},
volume = {Volume 19},
pages = {8555--8580},
doi = {10.2147/dddt.s550340}
}
EUVIMED